RAD52 and chronic myelogenous leukemia, BCR-ABL1 positive: If RAD52 is performing these functions in human cells, it may be a viable target for drugs to attenuate SSA events that contribute to therapy-related drug resistance and disease progression in patients with chronic myelogenous leukemia and other myeloproliferative disorders (Cramer et al. 2008; Fernandes et al. 2009).